Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Short

Showing results (511-520 of 659) with videos related to

Pageof 66
Sort By:
Cancer|April 16, 2019
Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysisElias J Jabbour, Koji Sasaki, Farhad Ravandi, et al.
BMJ Open Diabetes Research & Care|October 15, 2020
Lower resource utilization for patients with healed diabetic foot ulcers during participation in a prevention program with foot temperature monitoringAdam L Isaac, Timothy D Swartz, Mark L Miller, et al.
American Journal of Hematology|July 31, 2016
Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapyNicholas J Short, Christopher B Benton, Hsiang-Chun Chen, et al.
American Journal of Hematology|December 24, 2024
Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic DesignationJayastu Senapati, Hagop M Kantarjian, Fadi G Haddad, et al.
American Journal of Hematology|April 12, 2022
Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trialsKunhwa Kim, Marina Konopleva, Courtney D DiNardo, et al.
Cancer|July 13, 2021
Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclaxKunhwa Kim, Abhishek Maiti, Sanam Loghavi, et al.
JAMA Pediatrics|September 5, 2018
Association of Prenatal Maternal Depression and Anxiety Symptoms With Infant White Matter MicrostructureDouglas C Dean, Elizabeth M Planalp, William Wooten, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 25, 2024
Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid LeukemiaJason Yeh, Oren Pasvolsky, Rima M Saliba, et al.
Cancer|May 29, 2024
Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantationJayastu Senapati, Hagop M Kantarjian, Alexandre Bazinet, et al.
American Journal of Hematology|September 19, 2022
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypesDaniel Rivera, Kunhwa Kim, Rashmi Kanagal-Shamanna, et al.
Pageof 66

Showing results (511-520 of 659) with videos related to

Sort By:
Pageof 66
Cancer|April 16, 2019
Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysisElias J Jabbour, Koji Sasaki, Farhad Ravandi, et al.
BMJ Open Diabetes Research & Care|October 15, 2020
Lower resource utilization for patients with healed diabetic foot ulcers during participation in a prevention program with foot temperature monitoringAdam L Isaac, Timothy D Swartz, Mark L Miller, et al.
American Journal of Hematology|July 31, 2016
Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapyNicholas J Short, Christopher B Benton, Hsiang-Chun Chen, et al.
American Journal of Hematology|December 24, 2024
Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic DesignationJayastu Senapati, Hagop M Kantarjian, Fadi G Haddad, et al.
American Journal of Hematology|April 12, 2022
Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trialsKunhwa Kim, Marina Konopleva, Courtney D DiNardo, et al.
Cancer|July 13, 2021
Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclaxKunhwa Kim, Abhishek Maiti, Sanam Loghavi, et al.
JAMA Pediatrics|September 5, 2018
Association of Prenatal Maternal Depression and Anxiety Symptoms With Infant White Matter MicrostructureDouglas C Dean, Elizabeth M Planalp, William Wooten, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 25, 2024
Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid LeukemiaJason Yeh, Oren Pasvolsky, Rima M Saliba, et al.
Cancer|May 29, 2024
Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantationJayastu Senapati, Hagop M Kantarjian, Alexandre Bazinet, et al.
American Journal of Hematology|September 19, 2022
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypesDaniel Rivera, Kunhwa Kim, Rashmi Kanagal-Shamanna, et al.
Pageof 66